GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Context Therapeutics Inc (NAS:CNTX) » Definitions » Selling, General, & Admin. Expense

Context Therapeutics (Context Therapeutics) Selling, General, & Admin. Expense : $7.01 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Context Therapeutics Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Context Therapeutics's selling, general, & admin. expense for the three months ended in Mar. 2024 was $1.85 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2024 was $7.01 Mil.


Context Therapeutics Selling, General, & Admin. Expense Historical Data

The historical data trend for Context Therapeutics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Context Therapeutics Selling, General, & Admin. Expense Chart

Context Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
2.97 0.93 3.63 7.79 7.29

Context Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.13 1.83 1.70 1.63 1.85

Competitive Comparison of Context Therapeutics's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Context Therapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Context Therapeutics's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Context Therapeutics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Context Therapeutics's Selling, General, & Admin. Expense falls into.



Context Therapeutics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Context Therapeutics  (NAS:CNTX) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Context Therapeutics Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Context Therapeutics's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Context Therapeutics (Context Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103
Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.
Executives
Martin A. Lehr director, officer: Chief Executive Officer 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Jennifer Lynn Minai-azary officer: Chief Financial Officer 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Alex C. Levit officer: Chief Legal Officer, Corp. Sec 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Tarek Sahmoud officer: Chief Medical Officer 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Richard J Berman director 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Jennifer Evans Stacey director AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Linda West director C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD., #110, MALVERN PA 19355
Evan G. Dick officer: SVP of R&D 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
William F. Rencher officer: Head of CMC and Regulatory 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Philip W. Kantoff director 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104